A controversial ASCO presentation underscores risk Bristol, Nektar carry with experimental cancer drug
by Adam Feuerstein
Jun 03, 2018
2 minutes
On Saturday night, the controversy around the experimental cancer immunotherapy drug NKTR-214 ratcheted higher following a new data presentation at the American Society of Clinical Oncology annual meeting.
Nektar Therapeutics and Bristol-Myers Squibb, the owners of NKTR-214, are undertaking a hugely expensive program to run nearly two dozen clinical trials spanning 20 indications across nine types of solid tumors. Phase 3 studies in melanoma, kidney cancer, and
You’re reading a preview, subscribe to read more.
Start your free 30 days